目的 探討葛蘭心寧軟膠囊聯(lián)合雙嘧達(dá)莫片治療冠心病心絞痛的臨床療效。方法 選擇2019年6月—2021年6月在南陽(yáng)南石醫(yī)院治療的84例冠心病心絞痛患者，根據(jù)用藥的差別分成對(duì)照組（42例）和治療組（42例）。對(duì)照組口服雙嘧達(dá)莫片，50 mg/次，3次/d；治療組在對(duì)照組基礎(chǔ)上口服葛蘭心寧軟膠囊，1.16 g/次，2次/d。兩組均經(jīng)4周治療。觀察兩組患者臨床療效，比較治療前后兩組患者心絞痛發(fā)作次數(shù)和持續(xù)時(shí)間，GQOLI-74、SF-36、SAQ和臨床癥狀積分，及血清C反應(yīng)蛋白（CRP）、可溶性CD40配體（sCD40L）、白細(xì)胞介素-18（IL-18）、髓過(guò)氧化酶（MPO）、人可溶性細(xì)胞黏附分子（sICAM-1）和妊娠相關(guān)血漿蛋白-A（PAPP-A）水平。結(jié)果 經(jīng)治療，對(duì)照組總有效率為80.95%，顯著低于治療組的97.62%（P<0.05）。經(jīng)治療，兩組心絞痛發(fā)作次數(shù)、持續(xù)時(shí)間均顯著減少（P<0.05），但以治療組減少最明顯（P<0.05）。經(jīng)治療，兩組GQOLI-74、SF-36和SAQ積分明顯升高，臨床癥狀積分明顯降低（P<0.05），但治療組積分明顯好于對(duì)照組（P<0.05）。治療后，兩組患者血清CRP、sCD40L、IL-18、MPO、sICAM-1和PAPP-A水平明顯降低（P<0.05），且治療組降低更明顯（P<0.05）。結(jié)論 雙嘧達(dá)莫片聯(lián)合葛蘭心寧軟膠囊治療冠心病心絞痛不僅促進(jìn)癥狀改善，還能夠促進(jìn)機(jī)體細(xì)胞因子及生活質(zhì)量的改善，具有一定臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Gelan Xinning Soft Capsules combined with dipyridamole in treatment of angina pectoris of coronary heart disease. Methods Patients (84 cases) with angina pectoris of coronary heart disease in Nanshai Hospital of Nanyang from June 2019 to June 2021 were divided into control (42 cases) and treatment (42 cases) group according to different treatments. Patients in the control group were po administered with Dipyridamole Tablets, 50 mg/time, three times daily. Patients in the treatment group were po administered with Gelan Xinning Soft Capsules on the basis of the control group, 1.16 g/time, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical evaluation was evaluated, the frequency and duration of angina pectoris, the scores of related GQOLI-74, SF-36, SAQ and clinical symptom, and the levels of serological indexes CRP, sCD40L, IL-18, MPO, sICAM-1 and PAPP-A in two groups before and after treatment were compared.Results After treatment, the clinical effective rate in the control group was 80.95%, which was significantly lower than 97.62% in the treatment group (P < 0.05). After treatment, the attack frequencies and duration of angina pectoris were significantly decreased in two groups (P < 0.05), but the treatment group decreased most obviously (P< 0.05). After treatment, the scores of GQOLI-74, SF-36 and SAQ in two groups were significantly increased, while the scores of clinical symptoms were significantly decreased (P < 0.05), and the score of the treatment group was significantly better than that of the control group (P < 0.05). After treatment, the serum levels of CRP, sCD40L, IL-18, MPO, sICAM-1 and PAPP-An in two groups were significantly decreased (P < 0.05), especially in the treatment group (P < 0.05).Conclusion Gelan Xinning Soft Capsules combined with dipyridamole in treatment of angina pectoris of coronary heart disease can not only promote the improvement of symptoms, but also the cytokines and quality of life, which has a certain clinical application value.

R972

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（201701029）